Invimestrocel is under clinical development by Athersys and currently in Phase III for Acute Ischemic Stroke. According to GlobalData, Phase III drugs for Acute Ischemic Stroke have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Invimestrocel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Invimestrocel overview

Invimestrocel (PF05285401) is under development for the treatment of acute ischemic stroke, congestive heart failure, critical limb ischemia, peripheral arterial disease (PAD)/pulmonary vascular disease (PVD), multiple sclerosis, trauma, traumatic brain injury, spinal cord injury, solid organ transplantation, acute ischemic stroke, hemorrhagic stroke, for use in hematopoietic stem cell transplantation and pulmonary disorders such as pneumonia-induced acute respiratory distress syndrome (ARDS) and ARDS caused by coronavirus disease 2019 (COVID-19). The drug candidate is administered as an intravenous infusion. MultiStem is a biologic therapy that consists of undifferentiated human stem cells obtained from adult bone marrow or other non-embryonic tissue sources. It is a stem cell platform based on the multipotent adult progenitor cell (MAPC) technology.

It was also under development for acute leukemia, chronic myelocytic leukemia (CML), myelodysplastic syndrome (myelodysplasia), ulcerative colitis, type 1 diabetes, graft versus host disease (GVHD), acute myocardial infarction, Hurler’s syndrome, cerebral infarction and Parkinson's disease.

Athersys overview

Athersys is a biotechnology company that discovers and develops novel and proprietary therapies in the field of regenerative medicine. It is investigating its lead platform, MultiStem, a patented stem cell product for treating chronic conditions such as cardiovascular diseases, inflammatory and immune disorders, neurological, and pulmonary disorders. The company’s MultiStem program includes product candidates at various levels of clinical trials for treating acute myocardial infarction, traumatic brain injury, vascular disease, acute pulmonary distress, wound healing, organ reperfusion, bone marrow/hematopoietic stem cell transplantation, ischemic stroke, and autoimmune disease. The company’s pipeline consists of therapeutic product development programs in multiple disease areas, through the application of proprietary technologies. Athersys is headquartered in Cleveland, Ohio, the US.

For a complete picture of Invimestrocel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.